Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 8/20 | 0.59 |
| ▸ | HTR3E known ✓ | A5X5Y0 | 1/20 | 0.59 |
| ▸ | HTR3B known ✓ | O95264 | 1/20 | 0.59 |
| ▸ | HTR3D known ✓ | Q70Z44 | 1/20 | 0.59 |
| ▸ | HTR3C known ✓ | Q8WXA8 | 1/20 | 0.59 |
| ▸ | ADRB1 known ✓ | P08588 | 3/20 | 0.56 |
| ▸ | HTR1A known ✓ | P08908 | 8/20 | 0.52 |
| ▸ | KDR known ✓ | P35968 | 1/20 | 0.49 |
| ▸ | HTR6 known ✓ | P50406 | 1/20 | 0.48 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 known ✓ | P31645 | 1/20 | 0.48 |
| ▸ | HTR7 known ✓ | P34969 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL706971 | 0.98 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL30609639 | 0.98 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL6162084 | 0.85 | HTR1A (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL4238177 | 0.84 | ADRB1 (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL2534803 | 0.82 | HTR3A (0.68) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| Hydrochloric Acid SCHEMBL4331979 | 0.82 | KDR (0.51) | HTR3AHTR1AKDRHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL29883289 | 0.82 | KDR (0.51) | HTR3AHTR1AKDRHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5987897 | 0.82 | KDR (0.51) | HTR3AHTR1AKDRHTR6SLC6A2 | |
| Hydrochloric Acid SCHEMBL5988236 | 0.81 | ADRB1 (0.55) | HTR3AADRB1HTR1AKDRHTR6 | |
| SCHEMBL29557426 | 0.80 | KDR (0.53) | HTR3AHTR1AKDRHTR6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187497-B2 | Substituted pyrido[3,2-e]pyrrolo[1,2-a]pyrazines as inhibitors of poly(ADP-ribose)polymerase (PARP) | TAKEDA PHAMACEUTICAL COMPANY LIMITED (JP) | 2015-11-17 | — | — | US | disclosed |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-8822470-B2 | Substituted pyrido[2,3-b]pyrazines | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-02 | — | — | US | disclosed |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-10-17 | — | — | US | disclosed |
| US-8450323-B2 | Substituted derivatives of pyrido[3,2-e][1,4]thiazino[4,3-a]pyrazine and pyrido[3,2-e][1,4]oxazino[4,3-a]pyrazine | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-05-28 | — | — | US | disclosed |
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-17 | — | — | US | disclosed |
| US-8124606-B2 | Substituted 7,8,9,10-tetrahydro-5H-dipyrido[1,2-a:3′,2′-e]pyrazin-6(6aH)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-28 | — | — | US | disclosed |
| EP-2389379-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | Takeda Pharmaceutical Company Limited (JP) | 2011-11-30 | — | — | EP | disclosed |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-06-30 | — | — | US | disclosed |
| US-7928105-B2 | Substituted 6a,7,8,9-tetrahydropyrido[3,2-e]pyrrolo[1,2-a]pyrazin-6(5H)-ones | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-07-29 | — | — | US | disclosed |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED INTELLECTUAL PROPERTY DEPARTMENT (JP) | 2006-10-05 | — | — | US | disclosed |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2006-07-27 | — | — | US | disclosed |
| EP-1562898-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2005-08-17 | — | — | EP | disclosed |
| EP-1029851-B1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2005-04-20 | — | — | EP | disclosed |
| WO-2004046107-A1 | INDOLE DERIVATIVES AS SOMATOSTATIN AGONISTS OR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-03 | — | — | WO | disclosed |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-03-20 | — | — | US | disclosed |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION | 2003-01-23 | — | — | US | disclosed |
| US-6455528-B1 | TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT | MITSUBISHI PHARMA CORPORATION (JP) | 2002-09-24 | — | — | US | disclosed |
| EP-1029851-A1 | PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-08-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190763-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | HTR3A 1608/4885HTR3E 1012/4885HTR3B 1677/4885 |
| US-20060223826-A1 | Indole derivatives as somatostatin agonists or antagonists | SSTR1, SSTR3, NPY1R | HTR3A 74/4885HTR3E 139/4885HTR3B 97/4885 |
| US-20120122835-A1 | Poly (ADP-Ribose) Polymerase (PARP) Inhibitors | PARP1, PARP3, PARP2 | HTR3A 1608/4885HTR3E 1012/4885HTR3B 1677/4885 |
| US-20030055064-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | HTR3A 942/4885HTR3E 1448/4885HTR3B 1969/4885 |
| US-20110158989-A1 | Poly (ADP-Ribose) Polymerase (PARP) INHIBITORS | PARP1, PARP3, PARP2 | HTR3A 1608/4885HTR3E 1012/4885HTR3B 1677/4885 |
| US-20030018034-A1 | Piperazine compounds and medicinal use thereof | TNF, IL5, CCR10 | HTR3A 970/4885HTR3E 1455/4885HTR3B 2045/4885 |
| US-20060167014-A1 | Piperazine compounds and medicinal use thereof | TNF, CCR10, RELA | HTR3A 1098/4885HTR3E 1331/4885HTR3B 1610/4885 |
| US-20150031652-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | HTR3A 1608/4885HTR3E 1012/4885HTR3B 1677/4885 |
| US-20130274239-A1 | POLY (ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | PARP1, PARP3, PARP2 | HTR3A 1608/4885HTR3E 1012/4885HTR3B 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.